Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA

Sponsor
China Medical University, China
Study ID
NCT03116555
Phase
PHASE2
Status
Unknown

Conditions

  • Metastatic Gastric Adenocarcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • Apatinib — DRUG
    Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
  • Irinotecan — DRUG
    Irinotecan was used as second line treatment with AGC

Study Details

This is a prospective, multicenter, single-group clinical study of Apatinib Plus Irinotecan as second-line treatment in locally advanced or metastatic gastric or gastroesophageal junctional adenocarcinoma.

Key Dates

Start date
Apr 5, 2017
Status verified
Nov 2019
Primary completion
Mar 31, 2020
Completion
Sep 30, 2020

Study Design

Enrollment
37 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Irinotecan plus apatinib
    Irinotecan: 180mg/m2, ivgtt,given on the first day; Apatinib: initial dose: 250mg,oral,once a day, after meal ( try to take the medicine at the same time each day). Repeat the therapeutic schedule every 3 weeks till progressive disease or intolerable toxicities.

Primary Outcome Measure

Progression Free Survival [PFS] [ Time Frame: 5-6 months ]

Central Contacts

Related Studies